Glenmark Pharmaceuticals is currently trading at Rs. 380.20, up by 2.90 points or 0.77% from its previous closing of Rs. 378.10 on the BSE.
The scrip opened at Rs. 379.00 and has touched a high and low of Rs. 383.00 and Rs. 373.70 respectively. So far 29464 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 353.35 on 23-Aug-2019.
Last one week high and low of the scrip stood at Rs. 383.00 and Rs. 353.35 respectively. The current market cap of the company is Rs. 10716.75 crore.
The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.72% and 14.71% respectively.
Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is recalling 31,224 tubes of Clotrimazole and Betamethasone Dipropionate cream USP, 1 percent/0.05 percent, 15 gram tubes. The recall is a nationwide within the United States.
Clotrimazole and Betamethasone Dipropionate cream is used on the skin to treat fungal infections of the feet, genitals, inner thighs and buttocks, arms and legs and other body parts.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).